In a landmark move, India’s Drug Controller General (DCGI) has approved the country’s first dengue vaccine for commercial use. With dengue cases rising every year, this comes as a major breakthrough for public health.

The vaccine, developed after years of clinical trials, promises to reduce severe symptoms and hospitalizations among dengue patients. Initially, it will be available in government hospitals in high-risk zones like Delhi, Kerala, and Maharashtra, before rolling out nationwide.

Key Points to Know:

• The vaccine is recommended for ages 9 to 45.

• It requires 2 doses, 3 months apart.

• Mild fever and body ache are common side effects.

Experts are calling it a “game-changer” in India’s fight against vector-borne diseases. If you live in or travel to dengue-prone areas, consult your doctor about vaccination.